ImmuCell (NASDAQ:ICCC) Share Price Passes Above Two Hundred Day Moving Average - Here's What Happened

Key Points

• ImmuCell shares have crossed above their 200-day moving average, trading at $6.13, up from a 200-day average of $5.89.
• The biotechnology company reported a quarterly EPS of $0.06 with a revenue of $6.45 million, reflecting a net margin of 6.23%.
• Institutional investors currently own 13.47% of ImmuCell stock, with notable increases in holdings by Northern Trust Corp and Geode Capital Management.

ImmuCell Corporation (NASDAQ:ICCC - Get Free Report)'s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $5.89 and traded as high as $6.42. ImmuCell shares last traded at $6.13, with a volume of 13,036 shares changing hands.

ImmuCell Stock Down 0.8%

The company has a debt-to-equity ratio of 0.28, a current ratio of 3.85 and a quick ratio of 1.99. The firm has a market capitalization of $52.99 million, a P/E ratio of 30.82 and a beta of 0.29. The company's 50-day simple moving average is $6.35 and its two-hundred day simple moving average is $5.91.

ImmuCell (NASDAQ:ICCC - Get Free Report) last released its earnings results on Thursday, August 14th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter. ImmuCell had a return on equity of 6.25% and a net margin of 6.23%.The firm had revenue of $6.45 million during the quarter.

Hedge Funds Weigh In On ImmuCell

A number of hedge funds and other institutional investors have recently made changes to their positions in ICCC. Geode Capital Management LLC increased its position in shares of ImmuCell by 4.2% during the second quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company's stock worth $500,000 after purchasing an additional 2,907 shares in the last quarter. Northern Trust Corp raised its holdings in shares of ImmuCell by 51.0% during the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock worth $229,000 after purchasing an additional 14,982 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new position in ImmuCell during the fourth quarter valued at $149,000. Institutional investors own 13.47% of the company's stock.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.